Everest Medicines Limited

DB:6HN Stock Report

Market Cap: €1.9b

Everest Medicines Valuation

Is 6HN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 6HN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 6HN (€5.75) is trading below our estimate of fair value (€19.34)

Significantly Below Fair Value: 6HN is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 6HN?

Key metric: As 6HN is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 6HN. This is calculated by dividing 6HN's market cap by their current revenue.
What is 6HN's PS Ratio?
PS Ratio35x
SalesCN¥418.55m
Market CapCN¥14.64b

Price to Sales Ratio vs Peers

How does 6HN's PS Ratio compare to its peers?

The above table shows the PS ratio for 6HN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average9.9x
BIO3 Biotest
1.5x3.6%€1.4b
FYB Formycon
15.8x24.6%€958.8m
2INV 2invest
8.7xn/a€67.3m
HPHA Heidelberg Pharma
13.5x16.6%€114.6m
6HN Everest Medicines
35x33.7%€15.6b

Price-To-Sales vs Peers: 6HN is expensive based on its Price-To-Sales Ratio (35x) compared to the peer average (9.9x).

Price to Sales Ratio vs Industry

How does 6HN's PS Ratio compare vs other companies in the DE Biotechs Industry?

5 CompaniesPrice / SalesEstimated GrowthMarket Cap
CNW co.don
0.7xn/aUS$6.97m
V9Z Aceragen
0.4xn/aUS$3.12m
PA8 Paion
0.2x30.2%US$2.78m
V9Z Aceragen
0.3x-161.8%US$2.18m
6HN 35.0xIndustry Avg. 8.3xNo. of Companies5PS0612182430+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 6HN is expensive based on its Price-To-Sales Ratio (35x) compared to the European Biotechs industry average (8.3x).

Price to Sales Ratio vs Fair Ratio

What is 6HN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

6HN PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio35x
Fair PS Ratio8.9x

Price-To-Sales vs Fair Ratio: 6HN is expensive based on its Price-To-Sales Ratio (35x) compared to the estimated Fair Price-To-Sales Ratio (8.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 6HN forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€5.75
€3.75
-34.9%
34.2%€6.85€3.07n/a7
Dec ’25€3.94
€3.03
-23.2%
6.9%€3.46€2.84n/a6
Nov ’25€3.56
€3.03
-15.0%
6.9%€3.46€2.84n/a6
Oct ’25€2.98
€3.03
+1.5%
6.9%€3.46€2.84n/a6
Sep ’25€2.34
€3.03
+29.3%
7.5%€3.50€2.83n/a6
Aug ’25€2.20
€3.08
+39.9%
7.6%€3.52€2.84n/a6
Jul ’25€2.22
€3.31
+49.3%
18.3%€4.70€2.83n/a7
Jun ’25€2.52
€3.31
+31.5%
18.3%€4.70€2.83n/a7
May ’25€2.80
€3.34
+19.2%
18.5%€4.75€2.86n/a7
Apr ’25€2.70
€3.34
+23.6%
18.5%€4.75€2.86n/a7
Mar ’25€2.74
€3.12
+13.8%
22.6%€4.76€2.51n/a7
Feb ’25€1.82
€3.10
+70.4%
22.3%€4.72€2.49n/a7
Jan ’25€2.30
€3.16
+37.2%
23.0%€4.77€2.21€5.657
Dec ’24€2.26
€3.12
+38.2%
22.9%€4.71€2.18€3.947
Nov ’24€3.48
€2.70
-22.5%
13.1%€3.09€2.21€3.566
Oct ’24€2.90
€2.70
-7.0%
13.1%€3.09€2.21€2.986
Sep ’24€2.04
€2.66
+30.6%
14.7%€3.40€2.13€2.347
Aug ’24€2.44
€2.55
+4.5%
21.4%€3.37€1.78€2.207
Jul ’24€2.76
€2.54
-7.8%
22.0%€3.38€1.78€2.227
Jun ’24€1.25
€2.61
+109.1%
21.1%€3.36€1.85€2.527
May ’24€1.60
€2.82
+76.2%
25.0%€4.08€1.87€2.808
Apr ’24€1.73
€2.90
+67.9%
22.6%€4.06€2.01€2.708
Mar ’24€2.08
€2.97
+42.6%
22.3%€4.14€1.88€2.749
Feb ’24€2.87
€2.89
+0.6%
23.3%€4.09€1.67€1.829
Jan ’24€1.99
€2.79
+40.3%
28.9%€4.11€1.65€2.309

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/05 08:31
End of Day Share Price 2025/01/03 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Everest Medicines Limited is covered by 13 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Bo LiBofA Global Research
Ziyu HeChina International Capital Corporation Limited
Jin ZhangChina International Capital Corporation Limited